Perioperative sunvozertinib for stage II-IIIB NSCLC with EGFR exon 20 insertion
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests the drug sunvozertinib before and after surgery for non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). It aims to see if the drug can help shrink tumors and improve outcomes for patients whose cancer is at stage II, IIIA, or IIIB.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer with an EGFR exon 20 insertion mutation.
- Your cancer stage must be II, IIIA, or IIIB (N2).
- You should be in generally good health, with a performance status of 0 or 1.
- You must have at least one measurable tumor that can be tracked by scans.
- Your blood counts, liver, and kidney function must be within specific limits.
- You cannot have other active cancers, serious heart problems, or a history of lung scarring (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral drugs, sunvozertinib and anlotinib, taken together for people with advanced lung cancer that has an EGFR mutation and has gotten worse after EGFR targeted therapy. The goal is to see if this combination helps control cancer better than standard options.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
This trial tests the drug sunvozertinib given after surgery to see if it prevents lung cancer from coming back. It is for people with early-stage non-small cell lung cancer that has specific changes in the EGFR gene (exon20 insertion or PACC mutations).
This trial tests a drug called sunvozertinib in people with advanced non-small cell lung cancer (NSCLC) that has not been treated yet. It is for those who have certain uncommon changes in the EGFR gene. The drug may shrink tumors or stop them from growing.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.